Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent T Ho

Showing results (31-40 of 227) with videos related to

Pageof 23
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 23, 2009
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantationVincent T Ho, Julie Aldridge, Haesook T Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 1, 2013
Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantationGita Thanarajasingam, Haesook T Kim, Corey Cutler, et al.
Blood Advances|March 12, 2021
Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantationEmily Baumrin, Natalie E Izaguirre, Bruce Bausk, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 25, 2008
Costs of allogeneic hematopoietic cell transplantation with high-dose regimensAkiko M Saito, Corey Cutler, David Zahrieh, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 1, 2020
Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research AnalysisVincent T Ho, Andrew St Martin, Waleska S Pérez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 4, 2018
Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir ProphylaxisBettina M Knoll, Driele Peixoto, Sophia Koo, et al.
Open Forum Infectious Diseases|December 15, 2021
Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell TransplantMichaël Desjardins, Xhoi Mitre, Amy C Sherman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2007
A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantationPhilippe Armand, Haesook T Kim, Corey S Cutler, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 16, 2010
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced ageJohn Koreth, Julie Aldridge, Haesook T Kim, et al.
Blood Advances|February 11, 2021
Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal diseaseRahul S Vedula, Matthew P Cheng, Christine E Ronayne, et al.
Pageof 23

Showing results (31-40 of 227) with videos related to

Sort By:
Pageof 23
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 23, 2009
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantationVincent T Ho, Julie Aldridge, Haesook T Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 1, 2013
Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantationGita Thanarajasingam, Haesook T Kim, Corey Cutler, et al.
Blood Advances|March 12, 2021
Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantationEmily Baumrin, Natalie E Izaguirre, Bruce Bausk, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 25, 2008
Costs of allogeneic hematopoietic cell transplantation with high-dose regimensAkiko M Saito, Corey Cutler, David Zahrieh, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 1, 2020
Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research AnalysisVincent T Ho, Andrew St Martin, Waleska S Pérez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 4, 2018
Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir ProphylaxisBettina M Knoll, Driele Peixoto, Sophia Koo, et al.
Open Forum Infectious Diseases|December 15, 2021
Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell TransplantMichaël Desjardins, Xhoi Mitre, Amy C Sherman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2007
A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantationPhilippe Armand, Haesook T Kim, Corey S Cutler, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 16, 2010
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced ageJohn Koreth, Julie Aldridge, Haesook T Kim, et al.
Blood Advances|February 11, 2021
Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal diseaseRahul S Vedula, Matthew P Cheng, Christine E Ronayne, et al.
Pageof 23